Charles Schwab Investment Management Inc Immuneering Corp Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Immuneering Corp stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 12,000 shares of IMRX stock, worth $18,120. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,000Holding current value
$18,120% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding IMRX
# of Institutions
37Shares Held
4.78MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.6 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0808KShares$1.22 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD659KShares$995,1030.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$805,3790.0% of portfolio
-
Morgan Stanley New York, NY467KShares$705,5110.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $39.9M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...